• <em>MGA</em> deletion leads to Richter's transformation by modulating mitochondrial OXPHOS
• A Conformal Prediction Approach to Enhance Predictive Accuracy and Confidence in Machine Learning Application in Chronic Diseases
• A tumor suppressor of CLL: all (T-)bets are on
• Antineutrophil cytoplasmic antibody-negative pauci-immune glomerulonephritis in a patient with Waldenstrom macroglobulinaemia
• Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models
• Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
• Assessment for acceleration and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma using histologic and immunohistochemical features: a case series
• Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
• Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial
• BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia
• BTK inhibitors: past, present, and future
• Cardiac arrhythmias and overall outcomes with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia
• Case report: Germline <em>POT1</em> mutation in a patient with GIST and lung adenocarcinoma
• CD38/NAD(+) glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies
• CD4+ chronic lymphocytic leukemia in an 86-year-old male veteran: A case report
• CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
• Chronic hepatitis E virus-induced spinal cord atrophy in a patient with chronic lymphatic leukemia: a case report and interdisciplinary management proposal
• Chronic lymphocytic leukaemia
• Chronic Lymphocytic Leukemia (CLL)-Derived Extracellular Vesicles Educate Endothelial Cells to Become IL-6-Producing, CLL-Supportive Cells
• Chronic Lymphocytic Leukemia in Pregnancy: A Review of the Available Literature and the Pharmacological Challenges in Management
• Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs
• Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system
• Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy
• Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions
• Cryptococcosis at the university hospital of Marseille: A case series
• Disclosing tumor biology by means of molecular imaging in a patient with malignant melanoma and chronic lymphocytic leukemia
• Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
• Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies
• Evaluation of the Findings of Peripheral Blood Smear, Bone Marrow Aspiration and Biopsy, Iron Storage, and Immunophenotype in Patients with Chronic Lymphocytic Leukemia
• Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update
• Genomic structural variants analysis in leukemia by a novel cytogenetic technique: Optical genome mapping
• Hepatitis E virus and SARS-CoV-2 co-infection in an immunocompromised patient: A case report
• Herpes Simplex Virus Necrotic Lymphadenitis Masquerading as Lymphoma
• Holding the therapy in CLLp53: mechanisms to achieve durable responses
• IL-1 receptor antagonism reveals a yin-yang relationship between NFkappaB and interferon signaling in chronic lymphocytic leukemia
• Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia
• Immunophenotypic features of early haematopoietic and leukaemia stem cells
• Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma
• Information preferences of patients with chronic blood cancer: A qualitative investigation
• Integrative analysis reveals novel insights into juvenile idiopathic arthritis pathogenesis and shared molecular pathways with associated traits
• Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States
• Leukemia in India: Insights Into Incidence, Prevalence, Mortality, and Disability-Adjusted Life Years
• LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia
• MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia
• Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis
• Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors-A Literature Review
• MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells
• Multifocal Myelitis Associated with Chronic Lymphocytic Leukemia
• Multiple intra-axial lesions in a 57-year-old male with a history of B-cell chronic lymphocytic leukemia
• Multipocket Cage Enables the Binding of High-Order Bulky and Drug Guests Uncovered by MS Methodology
• Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
• Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia
• Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia
• New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling
• Non-coding variants impact cis-regulatory coordination in a cell type-specific manner
• Orbital Richter Transformation With Subsequent Orbital MALT-type Lymphoma in a Patient With Chronic Lymphocytic Leukemia
• Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis
• Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk
• PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia
• Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
• Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment
• Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications
• Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia
• Prediction of leukemia peptides using convolutional neural network and protein compositions
• Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study
• Rapidly progressive locked-in syndrome secondary to atypical herpes simplex virus-1 rhombencephalitis in an immunocompromised individual
• Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
• Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting
• Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax
• Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
• Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function
• RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia
• Robust and cost-effective CRISPR/Cas9 gene editing of primary tumor B cells in E-TCL1 model of chronic lymphocytic leukemia
• Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia
• Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents
• Standing on the Shoulders of the Giants: Dr. Kanti R Rai
• T-cell dysfunction in CLL is mediated through expression of SIGLEC-10 ligands CD24 and CD52 on CLL cells
• Targeting sphingolipid metabolism in chronic lymphocytic leukemia
• The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia
• The Impact of Anemia on the Survival of Patients Diagnosed With Low-Grade Malignant B-cell Lymphomas
• The new life of ibrutinib therapy in CLL: enhancing personalized approaches
• The NOTCH1 and miR-34a signaling network is affected by <em>TP53</em> alterations in CLL
• The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies
• The Utility of CD43 and CD200 in Differentiating Chronic Lymphocytic Leukemia from Other Mature B-Cell Neoplasms: A Cross Sectional Study
• The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
• Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis
• Topological Structures in the Space of Treatment-Naive Patients with Chronic Lymphocytic Leukemia
• Treatment of relapsed CLL "in the BAAG"?
• Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia
• Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
• Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies
• Updates on the biology of chronic lymphocytic leukemia: introductory editorial
• Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations
• Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia
• van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142
• Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
• Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study
• Vitamin D insufficiency in CLL: a modifiable prognostic factor?
• Washed microbiota transplantation in an elderly patient with lymphocytic leukemia and Clostridioides difficile infection: A case report illustrating a triumph over complexity
• Whole-Transcriptome Sequencing-Based Profiling of the Cutaneous Virome in Patients with Secondary Immunodeficiency